Company news
Vanda Pharmaceuticals Inc. news in 2020
Vanda Pharmaceuticals Inc.'s news releases, calls and decks from 2020, newest first.
FDA Approves HETLIOZ® (tasimelteon) for the Treatment of Nighttime Sleep Disturbances in Smith-Magenis Syndrome
November 30, 2020
Vanda Pharmaceuticals Reports Third Quarter 2020 Financial Results
October 27, 2020
Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VSJ-110 for Allergic Conjunctivitis
October 25, 2020
Vanda Pharmaceuticals to Announce Third Quarter 2020 Financial Results on October 28, 2020
October 20, 2020
Vanda Pharmaceuticals Provides Update on Tradipitant Development Program
August 30, 2020
Vanda Pharmaceuticals' Interim Analysis from ODYSSEY Study Shows Tradipitant may Accelerate Clinical Improvement in Patients with COVID-19 Pneumonia
August 17, 2020
Vanda Pharmaceuticals Reports Second Quarter 2020 Financial Results
August 4, 2020
FDA Accepts and Grants Priority Review of Vanda's Applications for HETLIOZ® (tasimelteon) in the Treatment of Smith-Magenis Syndrome
August 2, 2020
Vanda Pharmaceuticals to Announce Second Quarter 2020 Financial Results on August 5, 2020
July 28, 2020
FDA grants authorization for Individual Patient Expanded Access Protocol for the use of tradipitant for gastroparesis
July 12, 2020
Vanda Pharmaceuticals Announces Virtual 2020 Stockholder Meeting
May 25, 2020
Vanda Pharmaceuticals Wins Motion To Dismiss False Claims Act Lawsuit
May 19, 2020
Vanda Pharmaceuticals CEO's Proposal on Clinical Trial Data Sharing, COVID-19 and Remdesivir
May 19, 2020
Vanda Pharmaceuticals Announces Agreement with FDA on Resubmission of the Application for HETLIOZ® for the Treatment of Patients with Smith-Magenis Syndrome
May 12, 2020
Vanda Pharmaceuticals Reports First Quarter 2020 Financial Results
May 5, 2020
Vanda Pharmaceuticals to Announce First Quarter 2020 Financial Results on May 6, 2020
April 28, 2020
Vanda Pharmaceuticals, Northwell Health Conduct ODYSSEY Trial In Patients With Severe COVID-19 Pneumonia
April 14, 2020
Vanda Pharmaceuticals Announces Initiation of "CALYPSO" to Study the Role of Genetic Variation in COVID-19 Infections in Collaboration With University of Washington Medicine
April 14, 2020
Vanda Pharmaceuticals Inc. And The University of Illinois at Chicago Announce Partnership To Identify Novel Antivirals Against COVID-19
April 7, 2020
Vanda Pharmaceuticals Announces the Initiation of ODYSSEY, an FDA Approved Clinical Study of Tradipitant in Hospitalized Patients with Severe COVID-19 Pneumonia
April 1, 2020
Vanda Pharmaceuticals Announces Participation at March 2020 Investor Conferences
February 26, 2020
Vanda Reports results from the EPIONE study of Tradipitant in the treatment of Pruritus in Atopic Dermatitis
February 24, 2020
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results
February 24, 2020
Vanda Pharmaceuticals Appoints Stephen Ray Mitchell to Board of Directors
February 18, 2020
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results on February 25, 2020
February 17, 2020
Vanda Pharmaceuticals Comments on Court Ruling
January 30, 2020
Vanda Pharmaceuticals Wins Key U.S. Supreme Court Patent Ruling on Fanapt®
January 12, 2020